News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
1–36
Matches
48
Sources here
15
Companies here
2
Search results Stored financial headlines

Active search

48 matching headlines

Ticker or company: HELPMain company stories
Clear
Latest

Stock Titan Deals and strategy

Sirenia Capital (HELP) reports 3.03M-share Cybin stake including warrant shares

Sirenia Capital Management LP and Alex Silverstein have reported a beneficial ownership of 3,029,500 Common Shares in Cybin Inc., which includes 969,500 shares issuable upon the exercise of warrants. This stake represents 4.8% of Cybin's outstanding Common Shares, based on 61,984,078 shares as of June 29, 2026. The shares are held through investment funds managed by Sirenia, with …

Main company 🇺🇸 United States
Read at Stock Titan
Sharemaestro market context Trend signal active 52 weeks +67.7% · Next-week setup negative 38.8% HELP stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Just inNext headlines
www.marketscreener.com Earnings Main company 🇺🇸 United States

Cybin : Financial Statements Q1 27 FINAL

Cybin Inc., doing business as Helus Pharma, has released its unaudited condensed interim consolidated financial statements for the first quarter ended June 30, 2026. The company reported a net loss of $47,819 thousand for the period, compared to a net loss of $24,613 thousand …

HELP main company
Sharemaestro market context Trend signal active 52 weeks +67.7% · Next-week setup negative 38.8% HELP stored weekly price path from 22 Aug 2025 to 14 Aug 2026
seekingalpha.com Earnings Main company 🇺🇸 United States

Cybin reports Q1 results

* Cybin press release [https://seekingalpha.com/pr/20619592-helus-pharma-reports-first-quarter-fiscal-2027-financial-results-and-recent-business] (HELP [https://seekingalpha.com/symbol/HELP]): Q1 Net loss was $47.8 million for the quarter ended June 30, 2026, compared to a net loss of $24.6 million in the same period last year. * Cash totaled $166.4 million as of June 30, 2026. …

HELP main company
Sharemaestro market context Trend signal active 52 weeks +67.7% · Next-week setup negative 38.8% HELP stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

kalkine.ca Market update Main company 🇺🇸 United States

Cybin, Inc. Stock Surges 7.45% as Trading Activity Spikes and Market Attention Builds

Cybin, Inc. (CN:HELP) shares saw a significant 7.45% surge on August 12, 2026, driven by increased trading activity, though the exact catalyst remains unconfirmed. The clinical-stage biopharmaceutical company focuses on developing psychedelic-based therapies for mental health conditions like depression. Investors are advised to research …

HELP main company
Sharemaestro market context Trend signal active 52 weeks +67.7% · Next-week setup negative 38.8% HELP stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Market update Main company 🇺🇸 United States

Adage Capital reports 5.29% Cybin Inc. (HELP) ownership, 3.29M shares

Adage Capital Management, L.P. and associated parties have disclosed a 5.29% beneficial ownership in Cybin Inc. (HELP), totaling 3,289,250 common shares, which includes shares issuable from warrants. This ownership stake grants them shared voting and dispositive power over these shares. The filing, a Schedule …

HELP main company
Sharemaestro market context Trend signal active 52 weeks +67.7% · Next-week setup negative 38.8% HELP stored weekly price path from 22 Aug 2025 to 14 Aug 2026
kalkine.ca Market update Main company 🇺🇸 United States

Cybin Inc. (CN:HELP) Shares Under Pressure as Investor Caution Builds Around Psychedelic Sector

Cybin Inc. (CN:HELP), a clinical-stage biotechnology company focused on psychedelic-based therapeutics for mental health, saw its shares decline by 14.05% on August 10, 2026, due to cautious investor sentiment in the emerging healthcare sector. The company's business model relies on R&D and clinical advancement, …

HELP main company
Sharemaestro market context Trend signal active 52 weeks +67.7% · Next-week setup negative 38.8% HELP stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Market update Main company 🇺🇸 United States

Helus Pharma (HELP) CEO to Join Canaccord Genuity Growth Conference Fireside Chat

Helus Pharma (Cybin Inc.) CEO Michael Halstead will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026, at 12:00 p.m. EDT. The clinical-stage pharmaceutical company is developing novel serotonergic agonists (NSAs) for mental health conditions, including …

HELP main company
Sharemaestro market context Trend signal active 52 weeks +67.7% · Next-week setup negative 38.8% HELP stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Helus Pharma Market update Main company 🇺🇸 United States

Helus Pharma to Participate at the Canaccord Genuity 46th Annual Growth Conference in Boston - Mon, 08/10/2026 - 12:00

Helus Pharma (Nasdaq: HELP) will participate in the Canaccord Genuity 46th Annual Growth Conference in Boston on August 11-12, 2026. CEO Michael Halstead is scheduled to present in a fireside chat on Wednesday, August 12, at 12:00 p.m. EDT. The company, known for developing …

HELP main company
Sharemaestro market context Trend signal active 52 weeks +67.7% · Next-week setup negative 38.8% HELP stored weekly price path from 22 Aug 2025 to 14 Aug 2026
kalkine.ca Regulatory and legal Main company 🇺🇸 United States

Cybin Inc (CN:HELP) Shares Under Pressure as Psychedelic Medicine Uncertainty and Investor Risk Aversion Drive Volatility

Cybin Inc. (CN:HELP) shares dropped by 10.54% due to investor caution surrounding psychedelic medicine, regulatory uncertainties, and the inherent volatility of clinical-stage biotechnology companies. The company develops psychedelic-based therapies for mental health, but its valuation is highly dependent on successful clinical trials, regulatory approvals, …

HELP main company
Sharemaestro market context Trend signal active 52 weeks +67.7% · Next-week setup negative 38.8% HELP stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Yahoo! Finance Canada Earnings Main company 🇺🇸 United States

Cybin (HELP) Names New CEO, Is The Stock Still Cheap?

Cybin (HELP) has appointed Michael Halstead as its new CEO, leading to significant short-term share price momentum with a 48.47% return over 7 days and 118.64% over 90 days, despite a long-term decline. A Simply Wall St. narrative suggests the stock is 69.1% undervalued …

HELP main company
Sharemaestro market context Trend signal active 52 weeks +67.7% · Next-week setup negative 38.8% HELP stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Market update Main company 🇺🇸 United States

Helport AI Ltd (HPAI) Stock News Today

This article provides current stock information for Helport AI Ltd (HPAI), including its latest stock price, market capitalization, and P/E ratio. It notes that more news regarding the company's stock, earnings, analyst ratings, and key developments will be available soon. The page serves as …

HPAI main company
Sharemaestro market context Price below Trend Line 52 weeks -87.8% · Next-week setup negative 34.9% HPAI stored weekly price path from 22 Aug 2025 to 14 Aug 2026
kalkine.ca Market update Main company 🇺🇸 United States

Cybin Inc (CN:HELP) Rallies 4.62%: rebranded psychedelic-medicine developer is trading briskly after a new CEO and an ahead-of-schedule Phase 3 enrollment,

Cybin Inc, now operating as Helus Pharma (CN:HELP), saw its stock rally 4.62% to C$15.40 with high relative volume, following a new CEO appointment on August 3, 2026, and the early completion of Phase 3 trial enrollment on July 21, 2026. While no specific …

HELP main company
Sharemaestro market context Trend signal active 52 weeks +67.7% · Next-week setup negative 38.8% HELP stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Sahm Deals and strategy Main company 🇺🇸 United States

Could Helus Pharma’s New CEO Reframe Cybin’s (HELP) Path From Clinical Trials To Commercial Scale?

Helus Pharma appointed Michael Halstead as CEO, a move that could significantly influence Cybin's strategic direction. Halstead's extensive experience in commercialization and M&A in the biopharma sector may reshape how Cybin approaches growth, partnerships, and capital allocation, especially as it moves towards potential commercialization …

HELP main company
Sharemaestro market context Trend signal active 52 weeks +67.7% · Next-week setup negative 38.8% HELP stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Market source Deals and strategy Main company 🇺🇸 United States

Cybin (HELP) Is Up 33.1% After Hiring Helus Veteran Michael Halstead As CEO – Has The Bull Case Changed?

Cybin's stock (HELP) surged 33.1% after appointing Michael Halstead, a veteran from Helus Pharma, as its new CEO. Halstead brings 25 years of biopharma experience, including significant roles in acquisitions and commercialization of psychiatric drugs, which could transform Cybin's late-stage development. While this appointment …

HELP main company
Sharemaestro market context Trend signal active 52 weeks +67.7% · Next-week setup negative 38.8% HELP stored weekly price path from 22 Aug 2025 to 14 Aug 2026
kalkine.ca Earnings Main company 🇺🇸 United States

Cybin (Helus Pharma, HELP) Leaps 14% Ahead of Pivotal Depression Trial Data

Helus Pharma (formerly Cybin, stock symbol HELP) saw its shares jump 14.02% ahead of crucial Phase 3 trial data for its lead depression drug, HLP003, expected in Q4 2026. The company recently appointed a new CEO and completed trial enrollment ahead of schedule, with …

HELP main company
Sharemaestro market context Trend signal active 52 weeks +67.7% · Next-week setup negative 38.8% HELP stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Investing News Network Market update Main company 🇺🇸 United States

A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 Readout

Helus Pharma (Nasdaq: HELP) has appointed Michael Halstead, former President of Intra-Cellular Therapies, as CEO, effective immediately. This strategic move comes months before the company's pivotal Phase 3 data readout for HLP003, a novel serotonergic agonist for Major Depressive Disorder (MDD) which has received …

HELP main company
Sharemaestro market context Trend signal active 52 weeks +67.7% · Next-week setup negative 38.8% HELP stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Seeking Alpha Market update Main company 🇺🇸 United States

Cybin continues rally following CEO appointment, up another 13% (HELP:NASDAQ)

Shares of Cybin Inc. (HELP), a clinical-stage biopharmaceutical company focused on psychedelic-based treatments, rose over 13% on Wednesday. This continued a rally initiated by the announcement of Michael Halstead's appointment as CEO. The article also briefly discusses potential impacts of the CEO change on …

HELP main company
Sharemaestro market context Trend signal active 52 weeks +67.7% · Next-week setup negative 38.8% HELP stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Deals and strategy Main company 🇺🇸 United States

Helus Pharma (Nasdaq: HELP) hires Michael Halstead to steer Phase 3 MDD push

Helus Pharma (operating as Cybin Inc.) has appointed Michael Halstead as its new Chief Executive Officer, effective immediately. This appointment comes as the company advances its HLP003 program into Phase 3 for Major Depressive Disorder, with topline data expected in Q4 2026, and HLP004 …

HELP main company
Sharemaestro market context Trend signal active 52 weeks +67.7% · Next-week setup negative 38.8% HELP stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Bitget Earnings Main company 🇺🇸 United States

Cybin publishes corporate presentation on development of serotonergic agonists for depression, anxiety

Cybin Inc. published a corporate presentation detailing the development of its serotonergic agonists. The presentation highlights HLP003, an oral drug in Phase 3 for major depressive disorder with FDA Breakthrough Therapy Designation, targeting topline data for Q4 2026. Additionally, HLP004, an intramuscular drug for …

HELP main company
Sharemaestro market context Trend signal active 52 weeks +67.7% · Next-week setup negative 38.8% HELP stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Helport AI Ltd (HPAI) Income Statement

This article provides the quarterly and annual income statements for Helport AI Ltd (HPAI), offering insights into its financial performance. It includes detailed data on operating expenses, net non-operating interest income, special income, and net income, alongside FAQs on how to interpret these financial …

HPAI main company
Sharemaestro market context Price below Trend Line 52 weeks -87.8% · Next-week setup negative 34.9% HPAI stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Market source Market update Main company 🇺🇸 United States

Cybin (CYBN) Stock Fair Value Moves Lower As Analysts Rework Psychedelic Sector Assumptions

Cybin's fair value estimate has been reduced by 24% from US$49.46 to US$37.57, reflecting a re-evaluation of the psychedelic sector by analysts. While there's bullish sentiment around large pharma interest in psychedelic agents and impending FDA guidance, bearish sentiment stems from cautious valuation work …

HELP main company
Sharemaestro market context Trend signal active 52 weeks +67.7% · Next-week setup negative 38.8% HELP stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

HPAI|Helport AI Ltd|Price:0.441|Chg%:-0.018

Helport AI Ltd (HPAI) closed at $0.441, down 3.90%, with a market cap of $16.61 million. The stock has seen significant declines over the past year. Helport AI Limited focuses on providing AI technology and solutions to enterprise customer contact centers.

HPAI main company
Sharemaestro market context Price below Trend Line 52 weeks -87.8% · Next-week setup negative 34.9% HPAI stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Moomoo Analyst action Main company 🇺🇸 United States

Wells Fargo Initiates Cybin(HELP.US) With Buy Rating, Announces Target Price $16

Wells Fargo has initiated coverage of Cybin (HELP.US) with a Buy rating. The firm has set a target price of $16 for the company's shares. This indicates a positive outlook from Wells Fargo on Cybin's future performance.

HELP main company
Sharemaestro market context Trend signal active 52 weeks +67.7% · Next-week setup negative 38.8% HELP stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Helport AI Ltd (HPAI) Cash Flow

This article provides a detailed quarterly and annual cash flow statement for Helport AI Ltd (HPAI), covering operating, investing, and financing cash flows. It includes comprehensive financial figures and year-over-year changes up to FY2024Q1. The document also offers definitions and FAQs regarding different types …

HPAI main company
Sharemaestro market context Price below Trend Line 52 weeks -87.8% · Next-week setup negative 34.9% HPAI stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Helport AI Ltd (HPAI) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an overview of Helport AI Ltd (HPAI), including its current stock performance, market capitalization, and P/E ratio. It highlights the company's financial overview, analysis, and a peer comparison with other technology companies like Salesforce and Snowflake. The content suggests it's part …

HPAI main company
Sharemaestro market context Price below Trend Line 52 weeks -87.8% · Next-week setup negative 34.9% HPAI stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Analyst action Main company 🇺🇸 United States

Cybin Inc. (NASDAQ:HELP) Receives Average Recommendation of "Buy" from Analysts

Five analysts have unanimously given Cybin Inc. (NASDAQ:HELP) a "Buy" rating, with an average 1-year price target of $45.25. Wells Fargo recently initiated coverage with an "overweight" rating and a $16 price objective. The stock saw a 5% increase to $8.00 during Monday trading, …

HELP main company
Sharemaestro market context Trend signal active 52 weeks +67.7% · Next-week setup negative 38.8% HELP stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Market update Main company 🇺🇸 United States

Helport AI Ltd (HPAI) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Helport AI Ltd (HPAI), covering various metrics related to volatility, financial risk, and investment risk. It details the company's stock performance, including daily returns, maximum drawdown, Sharpe ratio, and liquidity. The data presented aims to help investors …

HPAI main company
Sharemaestro market context Price below Trend Line 52 weeks -87.8% · Next-week setup negative 34.9% HPAI stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Helport AI Ltd (HPAI) Balance Sheet

This article provides the quarterly and annual balance sheets for Helport AI Ltd (HPAI), allowing users to analyze the company's financial health and key ratios. It details assets, liabilities, and shareholders' equity over several fiscal quarters, offering insights into changes like cash levels, total …

HPAI main company
Sharemaestro market context Price below Trend Line 52 weeks -87.8% · Next-week setup negative 34.9% HPAI stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Helport AI Ltd (HPAI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

The article provides a revenue breakdown for Helport AI Ltd (HPAI) for the fiscal years 2023, 2024, and 2025. It details the company's revenue contribution by business segment, specifically AI service and AIBPO service, and by region, with Singapore accounting for 100% of the …

HPAI main company
Sharemaestro market context Price below Trend Line 52 weeks -87.8% · Next-week setup negative 34.9% HPAI stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Market update Main company 🇺🇸 United States

Helport AI Ltd (HPAI) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides a detailed breakdown of Helport AI Ltd's (HPAI) shareholder structure, listing major shareholders by proportion and type, including corporate and individual investors. It also presents institutional shareholding data over several quarters and recent shareholder activity with changes in holdings. Additionally, it …

HPAI main company
Sharemaestro market context Price below Trend Line 52 weeks -87.8% · Next-week setup negative 34.9% HPAI stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Market update Main company 🇺🇸 United States

Cybin Ord Shs (HELP) Institutional Confidence

This article from TradingKey focuses on the institutional confidence in Cybin Ord Shs (HELP). It highlights key institutional shareholders and their recent activity, showing significant increases in shares held by top firms like Point72 Asset Management and OrbiMed Advisors. The data provided includes the …

HELP main company
Sharemaestro market context Trend signal active 52 weeks +67.7% · Next-week setup negative 38.8% HELP stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Market update Main company 🇺🇸 United States

Helport AI Ltd (HPAI) Valuation: PE, PB & Fair Value Analysis

This page provides a valuation analysis for Helport AI Ltd (HPAI), including its P/E and PB ratios. The current stock price, market capitalization, and some performance metrics are displayed. The article seems to be an overview page for HPAI's financial data and analysis on …

HPAI main company
Sharemaestro market context Price below Trend Line 52 weeks -87.8% · Next-week setup negative 34.9% HPAI stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

HELP|Cybin Ord Shs|Price:7.620|Chg%:-0.110

This page provides a detailed overview of Cybin Ord Shs (HELP), including its current stock price, market capitalization, performance metrics, and key financial figures. It also features analyst ratings, peer comparisons, technical indicators, and major shareholders, alongside frequently asked questions about the company.

HELP main company
Sharemaestro market context Trend signal active 52 weeks +67.7% · Next-week setup negative 38.8% HELP stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

Cybin Inc. Revenue Breakdown – BOATS:HELP

This article provides a basic financial overview of Cybin Inc. (HELP) on the TradingView platform, specifically focusing on its revenue breakdown. It indicates the market status as closed with no trades and highlights functionality for viewing financials, documents, news, and community discussions. The article …

HELP main company
Sharemaestro market context Trend signal active 52 weeks +67.7% · Next-week setup negative 38.8% HELP stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Market update Main company 🇺🇸 United States

Helport AI Ltd (HPAI) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Helport AI Ltd (HPAI), detailing various indicators and moving averages. It summarizes the value and direction for indicators like MACD, RSI, and StochRSI, concluding with a "Sell" for most. The moving averages also largely indicate a "Sell" …

HPAI main company
Sharemaestro market context Price below Trend Line 52 weeks -87.8% · Next-week setup negative 34.9% HPAI stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Yahoo! Finance Canada Earnings Main company 🇺🇸 United States

Cybin D/B/A Helus Pharma (HELP) Stock Price, News, Quote & History

Cybin D/B/A Helus Pharma (HELP) is a clinical-stage pharmaceutical company focused on developing therapies for psychiatric and neurological conditions. The company's stock is currently trading at $7.62, down 1.42% at close, with a 1-year target estimate of $37.55. Key pipeline assets include HLP003 for …

HELP main company
Sharemaestro market context Trend signal active 52 weeks +67.7% · Next-week setup negative 38.8% HELP stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context